Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

A 13-week, randomized double-blind, placebo-controlled, cross-over trial of ziprasidone in bipolar spectrum disorder.

Patkar AA, Pae CU, Vöhringer PA, Mauer S, Narasimhan M, Dalley S, Loebel A, Masand PS, Ghaemi SN.

J Clin Psychopharmacol. 2015 Jun;35(3):319-23. doi: 10.1097/JCP.0000000000000323.

PMID:
25882763
2.

Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis.

Taylor DM, Cornelius V, Smith L, Young AH.

Acta Psychiatr Scand. 2014 Dec;130(6):452-69. doi: 10.1111/acps.12343. Epub 2014 Oct 6. Review.

PMID:
25283309
3.

A randomized, double-blind, placebo-controlled study of ziprasidone monotherapy in bipolar disorder with co-occurring lifetime panic or generalized anxiety disorder.

Suppes T, McElroy SL, Sheehan DV, Hidalgo RB, Cosgrove VE, Gwizdowski IS, Feldman NS.

J Clin Psychiatry. 2014 Jan;75(1):77-84. doi: 10.4088/JCP.12m08297.

PMID:
24345758
4.

Clinical and regulatory implications of active run-in phases in long-term studies for bipolar disorder.

Cipriani A, Barbui C, Rendell J, Geddes JR.

Acta Psychiatr Scand. 2014 May;129(5):328-42. doi: 10.1111/acps.12223. Epub 2013 Nov 30. Review.

PMID:
24289821
5.

Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder.

Findling RL, Cavuş I, Pappadopulos E, Vanderburg DG, Schwartz JH, Gundapaneni BK, DelBello MP.

J Child Adolesc Psychopharmacol. 2013 Oct;23(8):545-57. doi: 10.1089/cap.2012.0029. Epub 2013 Oct 10.

6.

Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 2: influence of protocol-specific eligibility criteria on signal detection.

Sachs GS, Vanderburg DG, Edman S, Karayal ON, Kolluri S, Bachinsky M, Cavus I.

J Clin Psychiatry. 2012 Nov;73(11):1420-5. doi: 10.4088/JCP.11m07389.

7.

Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial.

Sachs GS, Vanderburg DG, Karayal ON, Kolluri S, Bachinsky M, Cavus I.

J Clin Psychiatry. 2012 Nov;73(11):1412-9. doi: 10.4088/JCP.11m07388.

PMID:
23218157
8.

Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol.

Goikolea JM, Colom F, Torres I, Capapey J, Valentí M, Undurraga J, Grande I, Sanchez-Moreno J, Vieta E.

J Affect Disord. 2013 Jan 25;144(3):191-8. doi: 10.1016/j.jad.2012.07.038. Epub 2012 Oct 22. Review.

PMID:
23089129
9.

Achieving and sustaining remission in bipolar I disorder with ziprasidone : a post hoc analysis of a 24-week, double-blind, placebo-controlled study.

Pae CU, Masand PS, Mandel FS, O'Gorman C.

Clin Drug Investig. 2012 Nov;32(11):747-54. doi: 10.1007/s40261-012-0009-1.

PMID:
23026845
10.

Characterizing relapse prevention in bipolar disorder with adjunctive ziprasidone: clinical and methodological implications.

Bowden CL, Karayal ON, Schwartz JH, Gundapaneni BK, O'Gorman C.

J Affect Disord. 2013 Jan 10;144(1-2):171-5. doi: 10.1016/j.jad.2012.04.024. Epub 2012 Sep 21.

PMID:
22999893
11.

Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?

Lombardo I, Sachs G, Kolluri S, Kremer C, Yang R.

J Clin Psychopharmacol. 2012 Aug;32(4):470-8. doi: 10.1097/JCP.0b013e31825ccde5.

PMID:
22722504
12.

A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state.

Patkar A, Gilmer W, Pae CU, Vöhringer PA, Ziffra M, Pirok E, Mulligan M, Filkowski MM, Whitham EA, Holtzman NS, Thommi SB, Logvinenko T, Loebel A, Masand P, Ghaemi SN.

PLoS One. 2012;7(4):e34757. doi: 10.1371/journal.pone.0034757. Epub 2012 Apr 24.

13.

Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder.

Popovic D, Reinares M, Goikolea JM, Bonnin CM, Gonzalez-Pinto A, Vieta E.

Eur Neuropsychopharmacol. 2012 May;22(5):339-46. doi: 10.1016/j.euroneuro.2011.09.008. Epub 2011 Oct 15. Review.

PMID:
22000157
14.

Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profiles.

Kemp DE, Karayal ON, Calabrese JR, Sachs GS, Pappadopulos E, Ice KS, Siu CO, Vieta E.

Eur Neuropsychopharmacol. 2012 Feb;22(2):123-31. doi: 10.1016/j.euroneuro.2011.06.005. Epub 2011 Jul 28.

15.

Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.

Sachs GS, Ice KS, Chappell PB, Schwartz JH, Gurtovaya O, Vanderburg DG, Kasuba B.

J Clin Psychiatry. 2011 Oct;72(10):1413-22. doi: 10.4088/JCP.09m05934.

PMID:
21672493
17.

Assessments of suicidality in double-blind, placebo-controlled trials of ziprasidone.

Karayal ON, Anway SD, Batzar E, Vanderburg DG.

J Clin Psychiatry. 2011 Mar;72(3):367-75. doi: 10.4088/JCP.10m06281gre.

PMID:
21450154
18.

Impact of geographical and cultural factors on clinical trials in acute mania: lessons from a ziprasidone and haloperidol placebo-controlled study.

Vieta E, Pappadopulos E, Mandel FS, Lombardo I.

Int J Neuropsychopharmacol. 2011 Sep;14(8):1017-27. doi: 10.1017/S146114571100040X. Epub 2011 Mar 14.

PMID:
21396153
19.

Ziprasidone for maintenance treatment of bipolar I disorder in adults.

Dubovsky SL, Dubovsky AN.

Expert Opin Pharmacother. 2011 Apr;12(5):817-24. doi: 10.1517/14656566.2011.563237. Epub 2011 Mar 9.

PMID:
21385150
20.

Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial.

Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M.

J Clin Psychiatry. 2010 Feb;71(2):130-7. doi: 10.4088/JCP.09m05482yel. Epub 2010 Jan 26.

PMID:
20122373

Supplemental Content

Loading ...
Support Center